Company intelligence / Profile preview
Odylia Therapeutics
Atlanta, Georgia, United Statesodylia.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Odylia Therapeutics is a nonprofit biotech leveraging an Anc80 AAV vector-based gene therapy platform to develop treatments for rare inherited retinal and sensory disorders. They have three internal preclinical to IND-enabling programs and support over 15 external partner programs through their Brydge Solutions initiative, focusing on ultra-orphan indications often overlooked by traditional pharma due to market size.
- Therapeutic areas
- OphthalmologyRare Diseases
- Modalities
- Gene therapyRecombinant proteinViral vector
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Patient advocacy groupsAcademic research centers such as Massachusetts Eye & Ear and Harvard Medical SchoolEarly-stage biotech companies focused on rare disease/gene therapiesMore than fifteen partnerships through Brydge Solutions initiative supporting external programs in the rare disease space
Beyond the preview
Go deeper on Odylia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odylia Therapeutics.